Low-dose heparin as an antithrombotic agent

G. F. Gensini, F. Bonechi, A. M. Gori, A. Fortini, R. Paniccia, R. Lamberti, M. Attanasio, F. Martini, D. Prisco, G. G Neri Serneri

Research output: Contribution to journalArticlepeer-review


Heparin, after subcutaneous administration, has been found to be able to bind to endothelial receptors both in rabbits and in humans. N-sulphonate 35S-heparin remains bound in rabbits for at least 24 h and is able to enhance the inactivation process of thrombin and factor Xa. Heparin subcutaneously (200 U/kg) injected for 2 weeks resulted in an enhanced inactivation of thrombin and factor Xa by the endothelium. The antithrombin- enhancing activity persists longer than the anti-Xa activity. In man, daily subcutaneous administration of heparin (12,500 U/day) for 2 weeks significantly reduces the increased fibrinopeptide A plasma levels and normalizes the increased l25I-fibrinogen turnover. The present work indicates that heparin administration at a low dose represents a treatment able to remarkably enhance the antithrombotic properties of the vessel wall, independently of the presence of detectable heparin levels in the circulating blood.

Original languageEnglish
Pages (from-to)129-131
Number of pages3
JournalPathophysiology of Haemostasis and Thrombosis
Publication statusPublished - 1990


  • Anti-Xa activity
  • Antithrombin
  • Endothelium
  • Heparin-antithrombotic therapy

ASJC Scopus subject areas

  • Hematology
  • Physiology (medical)


Dive into the research topics of 'Low-dose heparin as an antithrombotic agent'. Together they form a unique fingerprint.

Cite this